Stock Evaluator: Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. CRDL

$0.97 -0.01 -0.82%
November 17, 2026 4:00:00 PM EST November 10, 2021 Volume: 347,400
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Commentary & Analysis


Financial Summary

Share Statistics CRDL Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $113.5 $433.9 24%
Shares Out (Mil) 83.1 46.5 58%
Institutional Ownership 82.6% 82.2% 50%
Float (Mil) 97.7 47.7 59%
Beta na 0.74 na
Avg Daily Volume (000s) 498 345 56%
Price Change
(52-week)
(3.9%) 52.0% 47%
Growth CRDL Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.4% na
Net Income (5yr) (8.8%) (1.6%) 30%
EPS (5yr) 12.2% 15.1% 51
Dividends (5yr) na 0.0% na
Cash Flow (5yr) (19.7%) (15.1%) 34%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 4 3 4
Current EPS ($0.068) ($0.222) ($0.230)
Month Ago EPS ($0.058) ($0.222) ($0.228)
# Rev Up 1 0 0
# Rev Down 0 1 1
Three Months Ago EPS ($0.063) ($0.227) ($0.212)
Year/Year Chg (15.0%) (21.8%) (81.3%)
Financials CRDL Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $289 na
Net Income (TTM) (Mil) ($26) ($11) 21%
EPS (TTM) ($0.240) ($0.600) 32%
Operating Cash Flow (TTM) (Mil) ($15) ($7) 17%
Net Cash Flow (TTM) (Mil) $13 $1 60%
Long-Term Debt (Q1) (Mil) $0 $6 0%
Enterprise Value (Q1) (Mil) $100 $331 22%
Valuation CRDL Industry
Median
Percentile
(All Stocks)
P/B 6.12 2.05 85%
P/E na 24.3 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.2 na
Ratios CRDL Industry
Median
Percentile
(All Stocks)
Gross Margin na 69.5% na
Net Margin na 3.9% na
ROA (162.5%) (23.3%) 2%
ROE (200.5%) (21.8%) 4%
Liabilities to Assets 16.1% 31.2% 10%
F-Score 4 3 33%

Cardiol Therapeutics Inc. did not pass any screens on 11/16/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors